Orexo Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Orexo sono diminuiti a un tasso medio annuo di -38.8%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 12.9%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 6.4%.

Informazioni chiave

-38.8%

Tasso di crescita degli utili

-38.6%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	30.5%
Tasso di crescita dei ricavi	-6.4%
Rendimento del capitale proprio	n/a
Margine netto	-17.7%
Prossimo aggiornamento sui guadagni	06 Feb 2025

Aggiornamenti sulle prestazioni recenti

Recent updates

Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 05

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Aug 02

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Jul 20

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Jun 14

Is Orexo (STO:ORX) A Risky Investment?

Apr 27

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 19

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Sep 09

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

May 26

Is Orexo (STO:ORX) Using Too Much Debt?

Apr 16

Ripartizione dei ricavi e delle spese

Come Orexo guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

OM:ORX Ricavi, spese e utili (SEK Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	596	-105	269	243
30 Jun 24	615	-97	280	270
31 Mar 24	619	-73	272	281
31 Dec 23	639	-128	306	303
30 Sep 23	629	-201	380	326
30 Jun 23	634	-195	347	319
31 Mar 23	624	-218	362	325
31 Dec 22	624	-178	325	318
30 Sep 22	612	-152	330	310
30 Jun 22	597	-177	348	297
31 Mar 22	592	-216	350	289
31 Dec 21	565	-223	372	272
30 Sep 21	580	-207	374	251
30 Jun 21	585	-240	409	238
31 Mar 21	621	-198	408	228
31 Dec 20	664	-84	389	225
30 Sep 20	743	4	368	225
30 Jun 20	824	201	322	216
31 Mar 20	846	288	341	197
31 Dec 19	845	219	332	181
30 Sep 19	834	232	413	170
30 Jun 19	819	182	421	166
31 Mar 19	818	178	364	159
31 Dec 18	783	138	358	167
30 Sep 18	747	113	275	156
30 Jun 18	697	79	268	147
31 Mar 18	656	32	274	149
31 Dec 17	644	23	287	134
30 Sep 17	637	19	230	133
30 Jun 17	653	27	256	128
31 Mar 17	682	29	303	118
31 Dec 16	706	29	324	132
30 Sep 16	752	-57	419	154
30 Jun 16	710	-139	434	173
31 Mar 16	648	-229	430	183
31 Dec 15	646	-210	439	173
30 Sep 15	636	-95	412	164
30 Jun 15	627	-85	389	173
31 Mar 15	617	-51	357	185
31 Dec 14	570	-57	307	198
30 Sep 14	449	-146	299	197
30 Jun 14	440	-138	288	208
31 Mar 14	391	-204	252	239
31 Dec 13	429	-155	251	238

Guadagni di qualità: ORX al momento non è redditizia.

Margine di profitto in crescita: ORX al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ORX non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 38.8% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ORX nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ORX non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 8.9% ).

Rendimento del capitale proprio

ROE elevato: Le passività di ORX superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Orexo Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Orexo AB (publ) to Report Q1, 2025 Results on May 06, 2025

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Price target decreased by 14% to kr18.50

No longer forecast to breakeven

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Orexo AB (publ) Initiates New Study of OX640 in Participants with Allergic Rhinitis

Orexo AB (publ) Announces Nomination Committee for the Annual General Meeting 2025

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Consensus EPS estimates fall by 45%

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 10% to kr21.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Orexo AB (publ) to Report Q1, 2025 Results on May 06, 2025

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Consensus EPS estimates upgraded to kr1.95 loss

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 127%

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings: Revenues exceed analyst expectations

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target decreased by 15% to kr31.00

First quarter 2023 earnings: Revenues exceed analyst expectations

Is Orexo (STO:ORX) A Risky Investment?

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Consensus forecasts updated

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Consensus forecasts updated

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

Consensus estimates of losses per share improve by 22%

First quarter 2022 earnings: Revenues in line with analyst expectations